Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
AssigneeChildren's Medical Center Corporation
InventorsMichael Klagsbrun, Shay Soker, Hua-Quan Miao, Seiji Takashima
Life of this patent
Estimating the term…
Abstract
The present invention relates to VEGF receptors (VEGFR) and neuropilins such as VEGF165R/NP-1 and NP-2 that are associated with metastatic potential of a malignant cell and their use in the diagnosis and prognosis of cancer. Preferred ones are VEGF165R/NP-1 and NP-2 but any neuropilin or VEGFR, where the constituents share at least about 85% homology with either of the above VEGF165R/NP-1 and NP-2 can be used. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.
Claims4
A method for determining prognosis for prostate cancer in an individual comprising:
- a. obtaining a tumor sample from said individual;
- b. measuring VEGF165R/NP-1 (SEQ ID NO:
- 1) receptor amounts to obtain a receptor level in said sample;
- c. correlating said receptor level with a baseline level, wherein the baseline level is determined by measuring levels of VEGF165R/NP-1 in a sample of disease free individuals;
- and
- d. correlating levels of receptor greater than the baseline with an indication of unfavorable prognosis and levels of receptor at the baseline or less with a favorable prognosis, whereby the prognosis of said patient is determined.
Dependencies are inferred from the claim text.